Robert Hobbs - Johns Hopkins University



CURRICULUM VITAE FOR ACADEMIC PROMOTIONThe Johns Hopkins University School of Medicine_____________________________ ______________________Robert Fran?ois Hobbs Demographic data(a) Assistant ProfessorDept. of Radiation OncologyWeinberg Building, B168(410)-502-1465(b) Assistant Professor (secondary appointment)Dept. of Radiology, Division of Nuclear MedicineCancer Research Building II, Room 4M.60(410)-502-8185(c) Assistant Professor (secondary appointment)Dept. of Oncologyrhobbs3@jhmi.eduEducation1986 Baccalauréat C Mention AB, Gymnase Jean Sturm, Strasbourg, FranceDEUG Physique (Associate’s in Physics)Licence de Physique (Bachelor’s in Physics)Ma?trise de Physique (Masters in Physics), including a two month internship at the CNRS (National Scientific Research Center)Université Louis Pasteur (currently known as the Université de Strasbourg), Strasbourg, France.1993-1994 ERASMUS Exchange StudentUniversit?t Wien, Vienna, Austria.1999-2000 Pre-Nursing program Nurse’s Aide InternshipSanta Fe Community College, Santa Fe, New Mexico, US.2000-2006 Ph. D. Graduate Student in Experimental Nuclear/Particle Physics,Dissertation title: “Measuring the Spin Correlated Coherent TransverseMomentum at PHENIX in Run3”.Department of Physics and AstronomyUniversity of New Mexico, Albuquerque, NM, US.2006-2011 Post-doctoral fellow Radioimmunotherapy and dosimetry (RTD) labDivision of Nuclear Medicine Department of RadiologySchool of MedicineJohns Hopkins University, Baltimore, MD, US.2011-2013 Medical physics resident Department of Radiation OncologySchool of MedicineJohns Hopkins University, Baltimore, MD, US.Certification2012ABR Medical Physics exam Part 1.2013ABR Medical Physics exam Part 2 – Therapeutic Physics.2014ABR Medical Physics oral exam Part 3 – Therapeutic Physics.Experience2001 – May 2006Research Assistant at the University of New Mexico, Department of Physics and Astronomy.PHENIX Collaborator from Fall 2002 – May 2006.Responsibilities/Areas of Research: Helped Build and conditioned Muon Tracker Station 1 North detector for the PHENIX collaboration at RHIC. Parameterized Fast Monte Carlo for event simulation in the muon arm of the PHENIX collaboration using GEANT3 (FORTRAN) and presented results at APS Four Corners meeting Oct. 2001. Researched and gave proposal (July 2002 at Brookhaven) for an extracted beam experiment in the AGS to measure beam polarization using frozen spin to measure polarization at RHIC.Calculated muon arm efficiency and acceptance for run3 PHENIX analyses.Online Calibration Expert in run3, helped develop online calibration software.Muon Tracker Expert for run3, run4 and run5 at PHENIX.Supervised and aided in construction of Muon Tracker chamber for trigger testing for PHENIX collaborators at RIKENAnalyzed run3 polarized proton data for coincidence events from semi-leptonic decays of open charm from gluon-gluon fusion in view of measuring gluon contribution to proton spin, presented at SPIN 2004.Analyzed jet-jet correlations in run3 and run5 polarized proton data in view of gauging orbital angular momentum contribution to proton spin, presented at PANIC 2005.May 2006 – June 2011 Post-doctoral fellow in the RTD lab at Johns HopkinsUniversity. July 2011 – June 2012 Research Associate in the RTD lab at Johns HopkinsUniversity. July 2012 – present Assistant Professor in the RTD lab at Johns HopkinsUniversity. Responsibilities/Areas of Research: Clinical Dosimetry.? WB planar, SPECT/CT, or PET/CT images are acquired at different time points following pre-therapeutic administration of radioactivity or radiolabeled substances of patients. The images are used to estimate absorbed dose to tumor and normal organs. Most analyses use 3D-RD, an in-house software package, based on EGSnrc Monte Carlo, and under continuous development, which also incorporates radiobiologic modeling. Specific projects include: high dose (or combined with external beam) 153Sm-EDTMP tumor dosimetry for treatment of metastatic osteosarcoma124I/131I treatment planning for 131I treatment of thyroid carcinomasdose-response studies for lymphoma and thyroid cancer renal toxicity and tumor dosimetry in radiopeptide therapy for neuroendocrine tumors (collaboration with University of Lausanne)Modeling.? Imaging is often too imprecise for the scale of information required. Modeling supplements imaging from clinical data or pharmacokinetic data from laboratory experiments to resolve specific issues, including: salivary gland toxicity study in 131I treatment of thyroid cancer (collaboration with University of Duisburg-Essen)cellular-based tumor model for BETR therapy efficacy and optimization of EBV-associated cancersartery wall toxicity from radioimmunotherapydevelopment of an alternate model for ?-particle dosimetry, in particular for organs at risk such as the bone marrow and kidneys where the localization of uptake and the short range of ?-emissions for standard dosimetric methodologies are grossly inadequate. July 2011 – Dec 2013 Medical Physics resident in the Radiation Oncology department of Johns Hopkins University. Rotations: Treatment planning for both 3D conformal plans and IMRT, as well as electron planning, matching electron fields.Brachytherapy, including HDR treatments of gynecological and endo-rectal cancers, prostate seed implants, eye plaques, therasphere therapy for liver mets, radium therapy for prostate bone missioning and modeling of a new Elekta Agility Linac at Sibley Hospital in Washington, D.C.Special Procedures, including TBI (assisted in commissioning the TBI for the Infinity), 4D-CT and ABC. Stereotactic treatment planning on Cyberknife and Synergy/Agility machines.Radiation Safety rotation with shielding calculations.Beam modeling in Pinnacle and validation for Sibley Agility and for Versa EB2.January 2014 – present Assistant Professor in the Radiation Oncology department of Johns Hopkins University. Responsibilities/Areas of Research: Combination treatment design, planning and therapy with external beam and internal emitters, in particular Sm-153-EDTMP with external beam for therapy of metastatic osteosarcoma (R01 with Dr. Loeb and Dr. Terezakis).Personalized absorbed dose-based treatment planning methodologies for unsealed brachytherapy, more particularly for 90Y theraspheres (R01 pending with Dr. Frey, Dr. Hong and Dr. Narang).Micro-scale modeling for Alpha-particle dosimetry. R01 as PI: current calculations of absorbed dose are not valid for alpha-emitters and clinical or pre-clinical toxicities are not consistent with dose calculations. The micro-to-macro methodology accounts for localized uptake and dose deposition.Radiobiology. Elected member of the MIRD Committee brought in for expertise and work on expanding radiobiological formalisms within radiopharmaceutical therapy.Modeling for assessment of toxicity to circulating blood and immune system from external beam radiation therapy.Response assessment and treatment planning using molecular imaging (principally 18F-FDG PET)Brachytherapy team member from January 2014 until present, including therasphere therapy for liver disease, and radium therapy for prostate bone metastases.TBI team member, including commissioning of VersaEB1 for TBI, from January 2014 until September 2015.Physicist of the Day (POD) team member from January 2014 until September 2015.4D-CT/ABC team member from January 2014 until September 2015.Machine physicist for Infinity from September 2014 until September 2015, including re-commissioning of electrons.Interim Brachytherapy manager - Shared administrative responsibilities for brachytherapy team. Clinical duties and supervision from September 2015 until June missioning of HDR Flexitron afterloader and applicators for GYN program.Chairman of Radiation Safety Committee since February 2017– responsible for radioactive sources inventory and disposal, safety education, shared RSO responsibilities.ResearchPeer-reviewed publications (medical physics)PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5QcmlkZWF1eDwvQXV0aG9yPjxZZWFyPjIwMDc8L1llYXI+

PFJlY051bT45PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj45PC9yZWMtbnVtYmVyPjxmb3Jl

aWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iMGVlYWRhZjA4ZjJ0dzNlcnZzNDV6d2VlNWZh

ZXo1YXByOXRkIj45PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwg

QXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5Qcmlk

ZWF1eCwgQS4gUi48L2F1dGhvcj48YXV0aG9yPlNvbmcsIEguPC9hdXRob3I+PGF1dGhvcj5Ib2Ji

cywgUi4gRi48L2F1dGhvcj48YXV0aG9yPkhlLCBCLjwvYXV0aG9yPjxhdXRob3I+RnJleSwgRS4g

Qy48L2F1dGhvcj48YXV0aG9yPkxhZGVuc29uLCBQLiBXLjwvYXV0aG9yPjxhdXRob3I+V2FobCwg

Ui4gTC48L2F1dGhvcj48YXV0aG9yPlNnb3Vyb3MsIEcuPC9hdXRob3I+PC9hdXRob3JzPjwvY29u

dHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+UnVzc2VsbCBILiBNb3JnYW4gRGVwYXJ0bWVudCBvZiBS

YWRpb2xvZ3kgYW5kIFJhZGlvbG9naWNhbCBTY2llbmNlcywgU2Nob29sIG9mIE1lZGljaW5lLCBK

b2hucyBIb3BraW5zIFVuaXZlcnNpdHksIEJhbHRpbW9yZSwgTWFyeWxhbmQgMjEyMzEsIFVTQS48

L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5UaHJlZS1kaW1lbnNpb25hbCByYWRpb2Jpb2xv

Z2ljIGRvc2ltZXRyeTogYXBwbGljYXRpb24gb2YgcmFkaW9iaW9sb2dpYyBtb2RlbGluZyB0byBw

YXRpZW50LXNwZWNpZmljIDMtZGltZW5zaW9uYWwgaW1hZ2luZy1iYXNlZCBpbnRlcm5hbCBkb3Np

bWV0cnk8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+SiBOdWNsIE1lZDwvc2Vjb25kYXJ5LXRpdGxl

PjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkogTnVjbCBNZWQ8L2Z1bGwtdGl0bGU+

PC9wZXJpb2RpY2FsPjxwYWdlcz4xMDA4LTE2PC9wYWdlcz48dm9sdW1lPjQ4PC92b2x1bWU+PG51

bWJlcj42PC9udW1iZXI+PGVkaXRpb24+MjAwNy8wNS8xNzwvZWRpdGlvbj48a2V5d29yZHM+PGtl

eXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPipJbWFnaW5nLCBUaHJlZS1EaW1lbnNpb25h

bDwva2V5d29yZD48a2V5d29yZD5Jb2RpbmUgUmFkaW9pc290b3Blczwva2V5d29yZD48a2V5d29y

ZD5Nb2RlbHMsIEJpb2xvZ2ljYWw8L2tleXdvcmQ+PGtleXdvcmQ+TW9udGUgQ2FybG8gTWV0aG9k

PC9rZXl3b3JkPjxrZXl3b3JkPk5lb3BsYXNtcy8qcmFkaW9ncmFwaHkvcmFkaW9udWNsaWRlIGlt

YWdpbmc8L2tleXdvcmQ+PGtleXdvcmQ+UGhhbnRvbXMsIEltYWdpbmc8L2tleXdvcmQ+PGtleXdv

cmQ+UmFkaWF0aW9uIERvc2FnZTwva2V5d29yZD48a2V5d29yZD5SYWRpb21ldHJ5PC9rZXl3b3Jk

PjxrZXl3b3JkPlJhZGlvcGhhcm1hY2V1dGljYWxzL2RpYWdub3N0aWMgdXNlPC9rZXl3b3JkPjxr

ZXl3b3JkPlJhZGlvdGhlcmFweSBQbGFubmluZywgQ29tcHV0ZXItQXNzaXN0ZWQvKm1ldGhvZHM8

L2tleXdvcmQ+PGtleXdvcmQ+VG9tb2dyYXBoeSwgRW1pc3Npb24tQ29tcHV0ZWQsIFNpbmdsZS1Q

aG90b24vbWV0aG9kczwva2V5d29yZD48a2V5d29yZD5Ub21vZ3JhcGh5LCBYLVJheSBDb21wdXRl

ZC9tZXRob2RzPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMDc8L3llYXI+PHB1

Yi1kYXRlcz48ZGF0ZT5KdW48L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4wMTYxLTU1

MDUgKFByaW50KTwvaXNibj48YWNjZXNzaW9uLW51bT4xNzUwNDg3NDwvYWNjZXNzaW9uLW51bT48

dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5uaWguZ292L2VudHJl

ei9xdWVyeS5mY2dpP2NtZD1SZXRyaWV2ZSZhbXA7ZGI9UHViTWVkJmFtcDtkb3B0PUNpdGF0aW9u

JmFtcDtsaXN0X3VpZHM9MTc1MDQ4NzQ8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGVsZWN0

cm9uaWMtcmVzb3VyY2UtbnVtPmpudW1lZC4xMDYuMDM4MDAwIFtwaWldJiN4RDsxMC4yOTY3L2pu

dW1lZC4xMDYuMDM4MDAwPC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48bGFuZ3VhZ2U+ZW5nPC9s

YW5ndWFnZT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5QcmlkZWF1eDwvQXV0aG9yPjxZZWFyPjIwMDc8L1llYXI+

PFJlY051bT45PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj45PC9yZWMtbnVtYmVyPjxmb3Jl

aWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iMGVlYWRhZjA4ZjJ0dzNlcnZzNDV6d2VlNWZh

ZXo1YXByOXRkIj45PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwg

QXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5Qcmlk

ZWF1eCwgQS4gUi48L2F1dGhvcj48YXV0aG9yPlNvbmcsIEguPC9hdXRob3I+PGF1dGhvcj5Ib2Ji

cywgUi4gRi48L2F1dGhvcj48YXV0aG9yPkhlLCBCLjwvYXV0aG9yPjxhdXRob3I+RnJleSwgRS4g

Qy48L2F1dGhvcj48YXV0aG9yPkxhZGVuc29uLCBQLiBXLjwvYXV0aG9yPjxhdXRob3I+V2FobCwg

Ui4gTC48L2F1dGhvcj48YXV0aG9yPlNnb3Vyb3MsIEcuPC9hdXRob3I+PC9hdXRob3JzPjwvY29u

dHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+UnVzc2VsbCBILiBNb3JnYW4gRGVwYXJ0bWVudCBvZiBS

YWRpb2xvZ3kgYW5kIFJhZGlvbG9naWNhbCBTY2llbmNlcywgU2Nob29sIG9mIE1lZGljaW5lLCBK

b2hucyBIb3BraW5zIFVuaXZlcnNpdHksIEJhbHRpbW9yZSwgTWFyeWxhbmQgMjEyMzEsIFVTQS48

L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5UaHJlZS1kaW1lbnNpb25hbCByYWRpb2Jpb2xv

Z2ljIGRvc2ltZXRyeTogYXBwbGljYXRpb24gb2YgcmFkaW9iaW9sb2dpYyBtb2RlbGluZyB0byBw

YXRpZW50LXNwZWNpZmljIDMtZGltZW5zaW9uYWwgaW1hZ2luZy1iYXNlZCBpbnRlcm5hbCBkb3Np

bWV0cnk8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+SiBOdWNsIE1lZDwvc2Vjb25kYXJ5LXRpdGxl

PjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkogTnVjbCBNZWQ8L2Z1bGwtdGl0bGU+

PC9wZXJpb2RpY2FsPjxwYWdlcz4xMDA4LTE2PC9wYWdlcz48dm9sdW1lPjQ4PC92b2x1bWU+PG51

bWJlcj42PC9udW1iZXI+PGVkaXRpb24+MjAwNy8wNS8xNzwvZWRpdGlvbj48a2V5d29yZHM+PGtl

eXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPipJbWFnaW5nLCBUaHJlZS1EaW1lbnNpb25h

bDwva2V5d29yZD48a2V5d29yZD5Jb2RpbmUgUmFkaW9pc290b3Blczwva2V5d29yZD48a2V5d29y

ZD5Nb2RlbHMsIEJpb2xvZ2ljYWw8L2tleXdvcmQ+PGtleXdvcmQ+TW9udGUgQ2FybG8gTWV0aG9k

PC9rZXl3b3JkPjxrZXl3b3JkPk5lb3BsYXNtcy8qcmFkaW9ncmFwaHkvcmFkaW9udWNsaWRlIGlt

YWdpbmc8L2tleXdvcmQ+PGtleXdvcmQ+UGhhbnRvbXMsIEltYWdpbmc8L2tleXdvcmQ+PGtleXdv

cmQ+UmFkaWF0aW9uIERvc2FnZTwva2V5d29yZD48a2V5d29yZD5SYWRpb21ldHJ5PC9rZXl3b3Jk

PjxrZXl3b3JkPlJhZGlvcGhhcm1hY2V1dGljYWxzL2RpYWdub3N0aWMgdXNlPC9rZXl3b3JkPjxr

ZXl3b3JkPlJhZGlvdGhlcmFweSBQbGFubmluZywgQ29tcHV0ZXItQXNzaXN0ZWQvKm1ldGhvZHM8

L2tleXdvcmQ+PGtleXdvcmQ+VG9tb2dyYXBoeSwgRW1pc3Npb24tQ29tcHV0ZWQsIFNpbmdsZS1Q

aG90b24vbWV0aG9kczwva2V5d29yZD48a2V5d29yZD5Ub21vZ3JhcGh5LCBYLVJheSBDb21wdXRl

ZC9tZXRob2RzPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMDc8L3llYXI+PHB1

Yi1kYXRlcz48ZGF0ZT5KdW48L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4wMTYxLTU1

MDUgKFByaW50KTwvaXNibj48YWNjZXNzaW9uLW51bT4xNzUwNDg3NDwvYWNjZXNzaW9uLW51bT48

dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5uaWguZ292L2VudHJl

ei9xdWVyeS5mY2dpP2NtZD1SZXRyaWV2ZSZhbXA7ZGI9UHViTWVkJmFtcDtkb3B0PUNpdGF0aW9u

JmFtcDtsaXN0X3VpZHM9MTc1MDQ4NzQ8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGVsZWN0

cm9uaWMtcmVzb3VyY2UtbnVtPmpudW1lZC4xMDYuMDM4MDAwIFtwaWldJiN4RDsxMC4yOTY3L2pu

dW1lZC4xMDYuMDM4MDAwPC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48bGFuZ3VhZ2U+ZW5nPC9s

YW5ndWFnZT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE.DATA Prideaux AR, Song H, Hobbs RF, He B, Frey EC, Ladenson PW, Wahl RL, Sgouros G. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med. 2007; 48(6):1008-16.Baechler S, Hobbs RF, Prideaux AR, Wahl RL, Sgouros G. Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Med Phys. 2008; 35(3):1123-34.Fu DX, Tanhehco YC, Chen J, Foss CA, Fox JJ, Chong JM, Hobbs RF, Fukayama M, Sgouros G, Kowalski J, Pomper MG, Ambinder RF. Bortezomib-induced enzyme-targeted radiotherapy in herpesvirus-associated tumors. Nat Med. 2008; 14(10):1118-22.Song H, Shahverdi K, Huso DL, Wang Y, Fox JJ, Hobbs RF, Gimi B, Gabrielson KL, Pomper MG, Tsui BM, Bhujwalla Z, Reilly RT, Sgouros G. An immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer. Clin Cancer Res. 2008; 14(19):6116-24.Baechler S, Hobbs RF, Prideaux AR, Recordon M, Bischof-Delaloye A, Sgouros G. Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan. Cancer Biother Radiopharm. 2008; 23(5):633-9.Hobbs RF, Sgouros G. Calculation of the biological effective dose (BED) for piecewise defined dose-rate fits. Med Phys. 2009, 36(3): 904-07.Loeb DM, Garrett-Mayer ES, Hobbs RF, Prideaux AR, Sgouros G, Shokek O, Wharam MD, Scott T, Schwartz CL. Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer. 2009; 115(11):2514-22.Hobbs RF, Wahl RL, Lodge MA, Javadi MS, Cho SY, Chien DT, Ewertz ME, Esaias CE, Ladenson PW, Sgouros G. 124I PET-Based 3D-RD dosimetry for pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. J Nucl Med. 2009; 50(11):1844-47.Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias CE, Apostolidis C, Morgenstern A, Sgouros G. Radioimmunotherapy of breast cancer metastases with alpha-particle-emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer Res. 2009; 69(23):8941-48.Hobbs RF, Baechler S, Senthamizhchelvan S, Prideaux AR, Esaias CE, Reinhardt M, Frey EC, Loeb DM, Sgouros G. A gamma camera count rate saturation correction method for whole-body planar imaging. Phys Med Biol. 2010; 55(3):817-831.Hobbs RF, Baechler S, Wahl RL, He B, Song H, Esaias CE, Frey EC, Jacene HA, Sgouros G. Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy. J Nucl Med. 2010; 51(3):368-75. Jentzen W, Hobbs RF, Stahl AR, Knust J, Sgouros G, Bockisch A. Pre-therapeutic 124I PET(/CT) dosimetry confirms low average absorbed doses per administered 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010; 37(5):884-895.Senthamizhchelvan S, Bravo PE, Esaias CE, Lodge MA, Merrill J, Hobbs RF, Sgouros G, Bengel FM. Human biodistribution and radiation dosimetry of 82Rb. J Nucl Med. 2010; 51(10):1592-99.Dieudonné A, Hobbs RF, Bolch WE, Sgouros G, Gardin I. Fine resolution voxel S-values for constructing absorbed dose distributions at variable voxel size. J Nucl Med. 2010; 51(10):1600-07.Loeb DM, Hobbs RF, Okoli A, Chen AR, Cho SY, Senthamizhchelvan S, Sgouros G, Shokek O, Wharam MD, Scott T, Schwartz CL. Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma. Cancer. 2010; 116(23):5470-78.Baechler S, Hobbs RF, Jacene HA, Wahl RL, Bochud FO, Sgouros G. Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab. J Nucl Med. 2010; 51(12):1878-84.Hobbs RF, McNutt T, Baechler S, He B, Esaias CE, Frey EC, Loeb DM, Wahl RL, Shokek O, Sgouros G. A treatment planning methodology for sequentially combining radiopharmaceutical therapy and external radiation therapy. Int J Radiat Oncol Biol Phys. 2011, 80(4):1256-62.Hobbs RF, Baechler S, Fu DX, Esaias CE, Pomper MG, Ambinder RF, Sgouros G. A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy. Med Phys. 2011; 38(6):2892-2903.Senthamizhchelvan S, Hobbs RF, Song H, Frey EC, Zhang Z, Armour EP, Wahl RL, Loeb DM, Sgouros G. Tumor dosimetry and response for 153Sm- ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma. J Nucl Med. 2012; 53(2):215-24. Hobbs RF?, Song H, Watchmann CJ, Bolch WE, Aksnes AK, Ramdahl T, Flux GD, Sgouros G. A bone marrow toxicity model for ???Ra alpha-emitter radiopharmaceutical therapy. Phy Med Biol. 2012; 57(10):3207-22.Hobbs RF?, Song H, Huso DL, Sundel M, Sgouros G. A nephron-based model of the kidneys for macro-to-micro α-particle dosimetry. Phys Med Biol. 2012; 57: 4403–24.Baechler S, Hobbs RF, Boubaker A, He B, Frey EC, Sgouros G. Three-dimensional radiobiological dosimetry for planning peptide receptor radionuclide therapy. Med Phys. 2012, 39(10): 6118-28.Dieudonné A*, Hobbs RF*, Lebtahi R, Maurel F, Baechler S, Wahl RL, Boubaker A, Leguludec D, Sgouros G, Gardin I. Study of the Impact of Tissue Density Heterogeneities on 3D Abdominal Dosimetry: Comparison Between Dose Kernel Convolution and Direct Monte Carlo methods. J Nucl Med. 2013, 54(2): 236-43.Hobbs RF, Jentzen W, Bockisch A, Sgouros G. Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET. Q J Nucl Med Mol Imaging. 2013, 57(1):79-91.Cheng L, Hobbs RF, Sgouros G, Frey EC. Improved dose-volume histogram estimates for radiopharmaceutical therapy by optimizing quantitative SPECT reconstruction parameters. Phys Med Biol. 2013, 58(5):3631–47.Hobbs RF?, Wahl RL, Frey EC, Kasamon YL, Jones RJ, Song H, Huang P, Sgouros G. Radiobiologically optimized combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin’s lymphoma. J Nucl Med. 2013, 54(9):1535-42.Song H, Hedayati M, Hobbs RF, Shao C, Morgenstern A, Wahl RL, DeWeese T, Sgouros G. Targeting aberrant DNA double strand break repair in triple negative breast cancer with alpha particle emitter radiolabeled anti-EGFR antibody. Mol Cancer Ther. 2013, 12(10):2043-54. Botta F, Mairani A, Hobbs RF, Vergara Gil A, Pacilio M, Parodi K, Cremonesi M, Coca Pérez MA, Di Dia A, Ferrari M, Guerriero F, Battistoni G, Pedroli G, Paganelli G, Torres Aroche LA, Sgouros G. Use of the FLUKA Monte Carlo code for 3D patient-specific dosimetry on PET-CT and SPECT-CT images. Phys Med Biol. 2013, 58(22): 8099-8120.Dholakia AS, Kumar R, Raman SP, Moore JA, Ellsworth S, McNutt T, Laheru DA, Jaffee E, Cameron JL, Tran PT, Hobbs RF, Wolfgang CL, Herman JM. Mapping Patterns of Local Recurrence Following Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: A new Approach to Adjuvant Radiation Field Design. Int J Radiat Oncol Biol Phys. 2013, 87(5): 1007-15.Hobbs RF?, Howell RW, Song H, Baechler S, Sgouros G. Redefining relative biological effectiveness in the context of the EQDX formalism: Implications for alpha-particle emitter therapy. Radiat Res 2014, 181(1):90-98.?Cheng L, Hobbs RF, Sgouros G, Frey EC. Development and Evaluation of Convergent and Accelerated Penalized SPECT Image Reconstruction Methods for Improved Dose-Volume Histogram Estimation in Radiopharmaceutical Therapy. Med Phys. Med Phys 2014 Nov;41(11):112507.Anizan N, Wang H, Zhou XC, Hobbs RF, Wahl RL, Frey EC. “Factors Affecting the Stability and Repeatability of Gamma Camera Calibration for Quantitative Imaging Applications Based on a Retrospective Review of Clinical Data”. EJNMMI Research 2014; 4(1):67.Banerjee SR, Foss CA, Pullambhatla M, Wang Y, Hobbs RF, Senthamizhchelvan S, Baidoo KE, Brechbiel MW, Mease RC, Sgouros G, Pomper MG. “Preclinical Evaluation of 86Y-Labeled Inhibitors of Prostate-Specific Membrane Antigen for Dosimetry Estimates.” J Nucl Med. 2015 Apr;56(4):628-34.Walker AJ, Chirindel A, Hobbs RF, Huynh-Le MP, Moore JA, Cho SY, Terezakis ST. “The Use of SUV Thresholding for Target Volume Delineation in Pediatric Hodgkin Lymphoma.” Pract Radiat Oncol. 2015 Jul-Aug;5(4):219-27.Kiess AP, Minn I, Chen Y, Hobbs RF, Sgouros G, Meese RC, Pullambhatla M, Foss CA, Pomper MG. “Antitumor Efficacy of Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen. J Nucl Med. 2015 Sep;56(9):1401-7.Plyku D, Loeb DM, Prideaux AR, Baechler S, Sgouros G, Hobbs RF?.“153Sm-EDTMP dosimetry for patients with metastatic osteosarcoma: application of a planar whole body gamma camera saturation recovery method and comparison with 3-dimensional dosimetry.” Cancer Biother Radiopharm. 2015 Nov;30(9):369-79.Woliner-van der Weg W, Schoffelen R, Hobbs RF, Gotthardt M, Goldenberg DM, Sharkey RM, Slump CH, van der Graaf WTA, Oyen WJG, Boerman OC, Sgouros G, Visser EP. “Tumor and red bone marrow dosimetry: Comparison of methods for prospective treatment planning in radioimmunotherapy”. EJNMMI Physics 2015 Dec; 2(1):5Abou DS, Ulmert D, Doucet M, Hobbs RF, Riddle RC, Thorek DLJ, “Whole-Body and Microenvironmental Localization of Radium-223 in Na?ve and Mouse Models of Prostate Cancer Metastasis.” J Natl Cancer Inst. 2015 Dec 18;108(5).Wild AT, Herman JM, Dholakia AS, Moningi S, Lu Y, Rosati LM, Hacker-Prietz A, Assadi RK, Saeed AM, Pawlik TM, Jaffee EM, Laheru DM, Tran PT, Weiss MJ, Wolfgang CL, Ford EC, Hobbs RF, Grossman SA, Ye X, Ellsworth SG. “Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Cancer.” Int J Radiat Oncol Biol Phys, 2016 Mar 1;94(3):571-9.Kiess AP, Minn I, Vaidyanathan G, Hobbs RF?, Shen C, Brummet M, Chen Y, Choi J, Koumarianou E, Baidoo K, Brechbiel MW, Mease RC, Sgouros G, Zalutsky MR, Pomper MG. “(2S)-2-(3-(1-Carboxy-5-(4-[211At]astatobenzamido)pentyl)ureido)-pentanedioic acid for PSMA-Targeted ?-particle Radiopharmaceutical Therapy”. J Nucl Med Mol Imaging, 2016 Oct;57(10):1569-1575.Yue J, Mauxion T, Reyes D, Lodge MA, Hobbs RF, Rong X, Sgouros G, Dong Y, Herman JM, Wahl RL, Geschwind JFH, Frey EC.“A Comparison of Quantitative Y-90 SPECT and PET Imaging in Post-Therapy Radioembolization of Liver Cancer: Patient Studies.” Med Phys, 2016 Oct;43(10):5779.Geyer AM, Schwarz BC, Hobbs RF, Sgouros,G, Bolch WE, “Quantitative impact of changes in marrow cellularity, skeletal size, and bone mineral density on active marrow dosimetry based upon a reference model”. Med Physics, 2017 Jan;44(1):272-283.Geyer AM, Schwarz BC, Hobbs RF, Sgouros,G, Bolch WE, “Depth-Dependent Concentration of Hematopoietic Stem Cells in the Adult Skeleton: Implications for Active Marrow Dosimetry”. Med Physics, 2017 Feb;44(2):747-761.Mauxion T, Du Y, Hobbs RF?, Geschwind JF, Herman JM?,?Yue J, Lodge MA, Reyes DK, Mirpour S, Wahl RL?, Frey EC. “Comparison of lung shunt fraction from pre-therapy Tc-99m MAA planar scintigraphy and post-therapy SPECT/CT for Y-90 glass microspheres radioembolization”. Med Phys, in press.Plyku D, Hobbs RF, Atkins F, van Nostrand D, Sgouros G. “Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in 124I-PET/CT based 3D radiobiological dosimetry (3D-RD) for 131I therapy of metastatic differentiated thyroid cancer (DTC) – organ dosimetry.” J Nucl Med Mol Imaging, e-pub.Coura-Filho GB, Willegaignon J, Fialho de Oliveira Hoff AA, Buchpiguel, CA Josefsson A, Hobbs RF, Sgouros G, Tatit Sapienza M, “68Ga-DOTATATE PET: temporal variation of SUVmax in normal tissues and neuroendocrine tumors.” Submitted to Eur J Nucl Med Mol Imaging.Craig-Schapiro R, Kamel IR, Sacerdote M, Canner J, Pittman M, Hicks C, Hacker-Prietz A, Hobbs RF, Armour EA, Efron JE, Wick EC, Azad NS, Herman JM, Gearhart SL, “Radiographic Predictors of Response to Endoluminal Brachytherapy for the Treatment of Rectal Cancer”, Submitted to J Rad Onc.Nedrow JR*, Josefsson A*, Park S, Hobbs RF, B?ck T, Brayton C, Bruchertseifer F, Morgenstern A, Sgouros G. “Pharmacokinetics, micro-scale distribution and dosimetry of alpha-emitter labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model”, Submitted to Cancer Res.Plyku D, Mena E, Szabo Z, Pomper MG, Cho SY, Sgouros G, Hobbs RF, “Combined Model-Based and Patient-Specific Dosimetry for Risk Evaluation of?18F-DCFPyL, a PSMA-Targeted PET Agent for Patients with Metastatic Prostate Cancer (PCa)” Submitted to J Nucl Med Mol Imaging.Geyer AM, Asokan A, Leibowitz J, Hobbs RF, Sgouros G, Ormerod B, Bolch WE. “Alpha-emitting radionuclide S values for renal dosimetry based upon image-based models of the human nephron.” )” Submitted to Med Phys.Geyer AM, Schwarz B, Hobbs RF, Sgouros G, Bolch WE. “Anatomically realistic macroscopic dosimetry models of the kidney for radionuclide therapy.” Submitted to Med Phys.? denotes corresponding author* denotes co-authorOver 50 Peer-reviewed publications (high energy physics, as a member of PHENIX collaboration)PatentsU.S. Patent Application No. 12/ 514,853. “System and Method for Determining Amount of Radioactive Material to Administer to a Patient”; G Sgouros, H Song, AR Prideaux, RF Hobbs.U.S. Patent Application No. 12/687,670. “Method and System for Administering Internal Radionuclide Therapy (IRT) and External Radiation Therapy (XRT)”; G Sgouros, RF Hobbs.U.S. Patent Application No. 12/690,471. “Method and System for Gamma Camera Count Rate Saturation Correction”; G Sgouros, RF Hobbs.JHU Ref.: C12217 (Pending) “Radiobiological Optimization of Combination Radiopharmaceutical Therapy Applied to Myeloablative Treatment of Non-Hodgkin's Lymphoma”; RF Hobbs, G Sgouros, RL Wahl.JHU Ref.: C12230 (Pending) “Methods of Identifying Surrogate Imaging Agents for Alpha-emitter Radiopharmaceuticals and their use in Treatment of Disease”; G Sgouros H Song, RF Hobbs. Grant participationActive NIH/NCI R01 CA157542-01, “Modeling Targeted Alpha Particle Therapy of Cancer”; Principal Investigator: RF Hobbs; Funding Awarded: $223,724; Current Effort: 8 %; Project Period: 4/1/2012-3/31/2018.NIH/NCI R01 CA201035, “Kallikrein-Targeted Alpha-Particle Therapy of Late-Stage Prostate Cancer”; Principal Investigator: DJ Thorek; ; Role in Project: Co-investigator; Current Effort: 6 %; Project Period: 12/15/16 – 11/30/20.NIH R01 CA163807 “Combination External Beam Radiotherapy with 153Sm-EDTMP to Treat High Risk Osteosarcoma”; Principal Investigator: DM Loeb; Role in Project: Co-investigator; Funding Awarded: $267,633 ; Current Effort: 7 %; Project Period: 3/1/2013-2/28/2018.NIH/NCI R01CA184228 “Small Molecule PSMA-targeted alpha therapy”; Principal Investigator: M Pomper; Role in Project: Co-investigator; Funding Awarded: $339,805 ; Current Effort: 5 %; Project Period: 5/1/2014-4/30/2019 NIH P50AC058236 “SPORE in Prostate Cancer”; Principal Investigator: W Nelson; Role in Project: Co-investigator; Funding Awarded: $1,564,392; Project Period: 9/1/2014-8/31/2019NIH/NCI R01 CA187037, “Combined Biologic and Radiopharmaceutical Therapy of Breast Cancer”; Principal Investigator: G Sgouros; Role in Project: co-Investigator; Funding: $357,747 Project Period: 4/1/2015-3/31/2020 SIBTECH, “Clinical development of efficient and cost-effective anti-angiogenic 177Lu radiopharmaceutical, scV/Lu, for VEGF receptor mediated targeting of angiogenic tumor vasculature”; Principal Investigator: M Pomper; Role in Project: co-Investigator; Funding: $180,000 Project Period: 7/1/2015-6/30/2018 Completed NIH/NCI R01 CA116477, “Dose-Response in Radionuclide Therapy”; Principal Investigator: G Sgouros; Role in Project: Post-doctoral fellow; Project Period: 5/1/2006-4/30/2011 NIH/NCI R01 CA138636, “BETR Therapy for Herpesvirus-associated Tumors” Principal Investigator: MG Pomper; Role in Project: Physicist; Project Period: 5/1/2010-4/30/2015.PCF “Promoter-driven Molecular Radiotherapy for Prostate Cancer”; Principal Investigator: MG Pomper; Role in Project: Co-Investigator; Project Period: 7/1/2012-6/30/2014.MDS Nordion “Imaging-based Dose Escalation of Y-90 Theraspheres”; Principal Investigator: JF Geschwind; Role in Project: Co-Investigator; Project Period: 5/1/2014-4/30/2015.NIH/NIBIB R01 EB013558, “Dose Reduction in Pediatric Molecular Imaging”; Principal Investigator: Frey/Sgouros (PI)Role in Project: Co-Investigator; Project Period:09/01/11 - 02/28/17NIH/NCI 2R01 CA116477, “Dose-Response in Radionuclide Therapy”; Principal Investigator: G Sgouros; Role in Project: Co-investigator; Funding Awarded: $222,274; Current Effort: 8 %; Project Period: 7/1/2011-6/30/2017.Pending NIH/NCI R01 CA201007, “PSMA-based radioloabeled theranostic agents for prostate cancer”; Principal Investigator: S Ray; Role in Project: co-Investigator; Funding: $250,000 Project Period: 4/1/2018 - 3/30/2023 NIH/NCI R01 CA200742, “Radioembolization of Liver Cancer – Patient Specific Optimization”; Principal Investigator: EC Frey, RF Hobbs, K Hong; Role in Project: co-PI; Funding: $465,268 Project Period: 4/1/2018 -3/30/2023 NIH/NCI CCSG CA006973, “SKCC Support Grant”; Principal Investigator: W Nelson; Role in Project: co-Investigator; Funding: $40,000,000 Project Period: 6/1/2017-3/31/2022. NIH/NCI 3R01 CA116477, “Dose-Response in Radionuclide Therapy”; Principal Investigator: G Sgouros, RF Hobbs; Role in Project: Co-PI; Funding: $250,000; Project Period: 9/1/2017-8/30/2022.?NIH/NCI R01 CA226789, “Modeling lymphocyte count and blood volume as a critical organ in radiation therapy”; Principal Investigator: RF Hobbs, SA Grossman, S Ellsworth; Role in Project: Co-PI; Funding: $250,000; Project Period: 3/1/2018-2/28/2023.NIH/SBIR (RAPID), “Service and Software Product for Optimally Combining External Beam Radiotherapy and Systemic Radiopharmaceutical Therapy – Phase I”; Principal Investigator: RF Hobbs; Funding: $28,896; Project Period: 10/1/2017 – 7/31/2018.NIH/SBIR (RAPID), “CycloSam (153Sm-DOTMP) Combined with External Beam Radiotherapy to Treat High Risk Osteosarcoma – Phase II”; Principal Investigator: DM Loeb; Role in Project: co-Investigator; Funding: $414,901; Project Period: 8/1/2018-7/31/2020.NAYA “CycloSam: A Novel Radiopharmaceutical to Treat Bone Metastatic Sarcoma”; Principal Investigator: DM Loeb; Role in Project: co-Investigator; Funding: $209,091; Project Period: 10/1/2017-9/30/2018.ONCOSIL J1770 “An open label, single arm pilot study of OncoSil?, administered to subjects with unresectable locally advanced pancreatic adenocarcinoma, given in combination with gemcitabine or gemcitabine+nab-paclitaxel chemotherapies” Principal Investigator: A Narang; Role in Project: Co-Investigator; Funding: $250,000; Project Period: 9/1/2017-8/31/2019.EducationalPublicationsSgouros G, Frey EC, Wahl RL, He B, Prideaux AR, Hobbs RF, Three-dimensional imaging-based radiobiological dosimetry. Semin Nucl Med 2008; 38(5):321-34.Sgouros G, Hobbs RF, Atkins FB, van Nostrand D, Ladenson PW, Wahl RL, 3D-Radiobiological Dosimetry (3D-RD) Patient-Specific Dosimetry with I-124 PET for I-131 therapy of Thyroid Cancer. Eur J Nuc Med Mol Imaging 2011; 38(S 1):S41–S47.Sgouros G, Hobbs RF, Song H, Modelling and dosimetry for alpha-particle therapy. Curr Radiopharm 2011; 4:261-265.Song H, Senthamizhchelvan S, Hobbs RF, Sgouros G, Alpha particle emitter radiolabeled antibody for metastatic cancer: what can we learn from heavy ion beam radiobiology. Antibodies 2012, 1:124-48.Sgouros G, Hobbs RF. “Dosimetry for radiopharmaceutical therapy” Semin Nucl Med. 2014, 44(3):172-8.Dieudonné A, Hobbs RF, Sanchez-Garcia M, Lebtahi R. “Absorbed dose calculation for treatment of liver neoplasms with 90Y-microspheres”. Reviews in Nucl Med Mol Imaging, in press.Book Chapters, Booklets, etc.Sgouros G, Hobbs RF. “Patient-Specific Dosimetry, Radiobiology, and the Previously-Treated Patient”. In “Therapeutic Nuclear Medicine”, RP Baum editor, 2013.van Nostrand D, Hobbs RF, Atkins FB, Sgouros G. “I-124 PET-CT Imaging of Differentiated Thyroid Cancer”. In “Thyroid Cancer: A Comprehensive Guide to Management”,3rd edition. D van Nostrand, L Wartofski editors, 2013.G Sgouros, RF Hobbs, D. Abou. “The role of pre-clinical models in radiopharmaceutical therapy”. In “Radiopharmaceutical Therapy as a Therapeutic Modality”, ASCO educational book, 2014.BJ Allen, T B?ck, AB Brill, DR Fisher, RF Hobbs, RW?Howell, MR McDevitt, RF Meredith, BW Miller, S?Palm, JC Roeske, S Sofou, H Song, G Sgouros, J Torgue, MR Zalutsky. “MIRD Monograph- Radiobiology and Dosimetry for Radiopharmaceuical Therapy with Alpha-Particle Emitters”, 2015.RF Hobbs, G Sgouros “Radiobiology” in “MIRD Primer for Absorbed Dose Calculations”, 2nd revised edition, G Sgouros editor, under final review.RF Hobbs “Worked Examples” in “MIRD Primer for Absorbed Dose Calculations”, 2nd revised edition, G Sgouros editor, under final review.WE Bolch, D Fisher, R Howell, RF Hobbs “Radiation Dose Calculations” in “MIRD Primer for Absorbed Dose Calculations”, 2nd revised edition, G Sgouros editor, under final review.B Brill, P Zanzonico, RF Hobbs “Uncertainties in Dose Calculations” in “MIRD Primer for Absorbed Dose Calculations”, 2nd revised edition, G Sgouros editor, under final review.Teaching experienceJanuary 2000 - May 2002Part-time Faculty. Physics (Conceptual Physics with labs) and Math (College Algebra, Intermediate Algebra), Santa Fe Community College.Spring 2001Teaching Assistant at the University of New Mexico, Physics Department. Second semester algebra-based Physics covering Electromagnetism and Optics.Summer 2002, Summer 2003 Part-time Instructor (College Physics), University of New Mexico 2011, 2014 Lecture series on radiobiology and dosimetry in therapeutic nuclear medicine for Johns Hopkins Department of Radiology residents.2015 - present Member of the Radiation Oncology Physics team teaching Radiation Physics to Medical Residents. Organizational ActivitiesMembership2012 – present Society of Nuclear Medicine and Molecular Imaging.2014 - present MIRD Committee (elected member)2014 - present American Brachytherapy Society2014 – present American Association of Medical Physics2016 – present Radiation ResearchConsultancyJanuary 2010 - September 2010Alpha particle dosimetry and modeling for ALGETA ASA, Oslo, NorwaySeptember 2015Bayer Pharmaceuticals.Journal ReviewerJournal of Nuclear MedicineEuropean Journal of Nuclear Medicine and Molecular ImagingMedical PhysicsPhysics in Medicine and BiologyNuklearmedizinCancer Biotherapy and RadiopharmaceuticalsEJNMMI ResearchPLoS OnePhysica Medica: European Journal of Medical PhysicsBritish Journal of RadiologyBioMed ResearchThyroidOncoTargetRadiation ResearchJournal EditorMedical Physics (Associate Editor)Journal of Targeted Alpha Therapy (Editorial Board)American Journal of Nuclear Medicine and Molecular Imaging (Associate Editor)Grant ReviewerAppel à Projets (AAP) plan Physique Cancer for INSERM (French government agency), 2011-2016.Agence Nationale pour la Recherche, (French government agency), 2013.Belgian National Cancer Institute, mitteesMedical Internal Radiation Dosimetry (MIRD) Task Group member on “Radiobiological Reference Human”. Medical Internal Radiation Dosimetry (MIRD) Task Group chair on “I-131 adjuvant therapy for thyroid cancer”. AAPM “Nuclear Medicine” Committee.Conference OrganizationSession co-chair “Physique” [French] (with N Chouin). CIRFA 2013, Montpellier, anizer of the MIRD/SNMMI “Radiopharmaceutical Dosimetry Symposium”, 2015, Baltimore, MD.Session co-chair “Radiobiology” (with L Strigari). RPDS 2015, Baltimore, MD.Session chair “Alpha-particle dosimetry”, SNMMI 2016, San Diego, CA.Conference Abstract ReviewerSNMMI 2014 – “Radiopharmaceutical Therapy” category.SNMMI 2016 – “Radiopharmaceutical Therapy” category.AAPM 2017 – “Brachytherapy”RecognitionAwards2008 SNM Travel awardInvited Talks“124I PET imaging in 3D-RD”. 25 min oral presentation. 124I in Biological and Medical Applications – 2nd Symposium 2009, Essen, Germany.“Radioimmunotherapy and dosimetry at the RTD lab at Johns Hopkins”. 50 min colloquium [French]. University of Lausanne 2009, Lausanne, Switzerland.“Radiopharmaceutical therapy: 3-dimensional personalized dosimetry and ??particle dosimetry”. 45 min colloquium. Washington Hospital Center 2011, Washington, DC, USA.“Arterial wall dosimetry in radiommunotherapy of lymphoma: modeling and dosimetry for critical small scale structures”. 25 min oral presentation. EMIT 2013, Washington DC, USA“124I PET thyroid dosimetry”. 30 min Continuing Education seminar. SNMMI 2013, Vancouver, Canada. “Dosimetry in nuclear medicine”. 40 min oral presentation [French]. CIRFA 2013, Montpellier, France.“223Ra Dosimetry”. 25 min oral presentation in Continuing Education categorical 'Theranostic nuclear medicine in oncology'. SNMMI 2014, St.Louis MO, USA.“Dosimetry-based treatment planning: personalized medicine in radiopharmaceutical therapy”. Oral presentation. ICI 2014, Chicago IL, USA. “Radiobiologically-based Combination Therapies”. Oral presentation. MIRD/SNMMI RPDS 2015, Baltimore MD, USA. “State of the Art and Outlook for Alpha Particle Dosimetry”. Oral presentation. Bayer Pharmaceuticals 2015, Berlin, Germany. “Radiopharmaceutical Therapy and Dosimetry”. Oral Presentaion. AAPM-MAC 2015, Baltimore, MD.“State of the Art and Outlook for Radiosystemic Therapy and Dosimetry”. Oral presentation. Radiation Research 2017, Cancun, Mexico. Conference AbstractsMedical PhysicsRF Hobbs, T McNutt, S Baechler, AR Prideaux, DM Loeb, O Shokek, G Sgouros. “Combined Internal Radionuclide Therapy (IRT) and External Radiation Therapy (XRT) treatment planning for 153Sm-EDTMP treatment of metastatic osteosarcoma”. 10 min oral presentation. SNM 2008, New Orleans, LA, USA. Travel award winner.S Baechler, RF Hobbs, HA Jacene, AR Prideaux, RL Wahl, G Sgouros, “A kinetics model of patient platelets after radioimmunotherapy”. 10 min oral presentation. SNM 2008, New Orleans, LA, USA.S Baechler, RF Hobbs, HA Jacene, AR Prideaux, RL Wahl, G Sgouros. “Factors Affecting Hematologic Toxicity after 90Y-Ibritumomab Tiuxetan or 131I-Tositumomab Radioimmunotherapy”. Poster presentation. SNM 2008, New Orleans, LA, USA.RF Hobbs, S Baechler, DX Fu, MG Pomper, RF Ambinder, G Sgouros. “Bortezomib-induced enzyme-targeted radiotherapy (BETR) Monte Carlo and dosimetry modeling with GEANT4”. 10 min oral presentation. EANM 2008, Munich, Germany. Highlighted talk.RF Hobbs, AR Prideaux, S Baechler, M Reinhardt, E Armour, EC Frey, DM Loeb, G Sgouros. “Tumor Dosimetry of Patients treated for Osteosarcoma with 153Sm-EDTMP”. Poster presentation. EANM 2008, Munich, Germany.RF Hobbs, W Jentzen, S Baechler, AR Prideaux, A Bockisch, G Sgouros. “Salivary gland Monte Carlo-based 3D-Radiobiological Dosimetry (3D-RD) in thyroid cancer patients from 124I PET Images”. Poster presentation. EANM 2008, Munich, Germany. W Jentzen, RF Hobbs, E Schneider, A Stahl, J Knust, G Sgouros, A Bockisch. “Iodine-124 PET(/CT) Dosimetry of the Salivary Glands”. Poster presentation. EANM 2008, Munich, Germany.RF Hobbs, DX Fu, MG Pomper, RF Ambinder, G Sgouros. “Bortezomib-induced enzyme-targeted radiotherapy (BETR) for AIDS-related malignancies: efficacy assessment by Monte Carlo and dosimetry modeling”. Poster presentation. ICMAOI 2008, Washington, DC, USA.RF Hobbs, MA Lodge, RL Wahl, MS Javadi, SY Cho, DT Chien, ME Ewertz, PW Ladenson, G Sgouros. “124I PET-Based 3D-RD Dosimetry for a Pediatric Thyroid Cancer Patient: Real-Time Treatment Planning”. 10 min oral presentation. SNM 2009, Toronto, Canada. RF Hobbs, S Baechler, S Senthamizhchelvan, H Song, B He, P Li, A Sibilio, EC Frey, RL Wahl, HA Jacene, G Sgouros. “Aortic Wall Modeling/Dosimetry in Lymphoma Patients Treated with Radioimmunotherapy”. 10 min oral presentation. SNM 2009, Toronto, Canada. S Baechler, RF Hobbs, A Bischof-Delaloye, A Boubaker, B He, EC Frey, G Sgouros. “The use of 3D patient-specific radiobiological dosimetry for kidneys in peptide receptor radionuclide therapy”. 10 min oral presentation. SNM 2009, Toronto, Canada.S Senthamizhchelvan, RF Hobbs, S Baechler, H Song, B He, EC Frey, CL Schwartz, DM Loeb, G Sgouros. “Patient specific 3-D Radiobiological Dosimetry (3D-RD) for 153Sm-EDTMP therapy of osteosarcoma”. 10 min oral presentation. SNM 2009, Toronto, Canada. L Cheng, RF Hobbs, N Song, G Sgouros, EC Frey. “Investigation of the Accuracy of Organ Dose Rate Histogram Estimates Obtained from Quantitative SPECT Images”. 10 min oral presentation. SNM 2010, Salt Lake City, USA.L Cheng, X He, RF Hobbs, WE Bolch, George Sgouros, EC Frey. “A convergent regularized SPECT reconstruction algorithm using anatomical prior for improved dose-volume histogram estimation”. Poster presentation. MIC 2010, Knoxville, TN, USA. G Sgouros, RF Hobbs, RL Wahl, PW Ladenson. “Clinical Implementation of patient-specific dosimetry, comparison with absorbed fraction-based methods”. 10 min oral presentation. IDOS 2010, Vienna, Austria.H Song, RF Hobbs, C Shao, G Sgouros. “Inhibiting DNA double strand break repair for alpha radioimmunotherapy. Poster presentation. AARC 2011, Orlando, FL, USA.RF Hobbs, H Song, CJ Watchmann, WE Bolch, AK Aksnes, T Ramdahl, GD Flux, G Sgouros. “A trabecular model of bone marrow toxicity for 223Ra alpha-emitter radiopharmaceutical therapy”. 10 min oral presentation. SNM 2011, San Antonio, TX, USA. S Baechler, F Camus, RF Hobbs, N Cherbuin, M Kosinski, JO Prior, G Sgouros, A Boubaker, FR Verdun. “Quantitative imaging of 90Y with PET/CT for reliable 3D patient-specific dosimetry after selective internal radiation therapy (SIRT)”. Poster presentation. SNM 2011, San Antonio, TX, USA. RF Hobbs, H Song, WE Bolch, CJ Watchmann, AK Aksnes, T Ramdahl, George Sgouros. “Modeling bone marrow toxicity from 223Ra radioimmunotherapy”. TAT – 7th Symposium 2011, Berlin, Germany.RF Hobbs, H Song, D Huso, M Sundel, G Sgouros. “Renal toxicity in targeted alpha therapy: advantages of a nephron-based dosimetry model”. 15 min oral presentation. TAT – 7th Symposium 2011, Berlin, Germany.H Song, RF Hobbs, C Shao, G Sgouros. “Alpha radioimmunotherapy of BRCA-1 deficient triple negative breast cancer”. 15 min oral presentation. TAT – 7th Symposium 2011, Berlin, Germany.G Sgouros, RF Hobbs, H Song. “Alpha-Particle Emitter Dosimetry: The Fallible Mean”. 15 min oral presentation. TAT – 7th Symposium 2011, Berlin, Germany.RF Hobbs, H Song, D Huso, M Sundel, G Sgouros. “A nephron-based dosimetry model for alpha-particle radiopharmaceutical therapy. Poster presentation. AAPM 2011, Vancouver, Canada.RF Hobbs, Y Le, EP Armour, J Efron, N Azad, R Kumar, L Diaz, H Qiu, G Sgouros, SL Gearhart, JM Herman. “Voxelized dose-response study in High Dose Rate 192Ir brachytherapy for rectal cancer.” Poster Presentation. WBC 2012, Barcelona, Spain.R Kumar, RF Hobbs, A Hacker-Prietz, H Quon, A Wild, EP Armour, JM Herman. “HDR Brachytherapy has a rapid tumor response and low normal tissue toxicity in non-melanoma skin cancer of the face.” Poster Presentation. WBC 2012, Barcelona, Spain.F Botta, A Mariani, G Battistoni, MA Coca Pérez, M Cremonesi, A Di Dia, M Ferrari, F Guerriero, RF Hobbs, M Pacilio, G Paganelli, K Parodi, G Pedroli, G Sgouros, LA Torres Aroche, A Vergara Gil. “Customization of FLUKA Monte Carlo code for dosimetry in radionuclide therapy based on patient specific PET/CT and SPECT/CT images.” Oral Presentation. 3rd EWGMCTP 2012, Sevilla, Spain.A Dieudonné, RF Hobbs, R Lebtahi, F Maurel, S Baechler, HA Jacene, RL Wahl, D Leguludec, G Sgouros, I Gardin. “Tissue Density Heterogeneities Influence and Simple Density Correction Method for 3D Abdominal Dosimetry in the Abdominal Region”. Poster Presentation. SNM 2012, Miami, FL, USA.F Botta, A Mariani, G Battistoni, MA Coca Pérez, M Cremonesi, A Di Dia, M Ferrari, RF Hobbs, M Pacilio, G Paganelli, K Parodi, G Pedroli, G Sgouros, LA Torres Aroche, A Vergara Gil. “Customization of FLUKA Monte Carlo code for dosimetry on PET-CT and SPECT-CT images. Comparison with 3DRD (EGS) and MCNP5.” Poster Presentation. SNM 2012, Miami, FL, USA.RF Hobbs, Y Le, EP Armour, J Efron, N Azad, L Diaz, RL Wahl, G Sgouros, SL Gearhart, JM Herman. “Changes in FDG-PET SUV correlate with voxel absorbed dose in HDR brachytherapy of rectal cancer.” 12 min oral presentation. SNM 2012, Miami, FL, USA. Highlighted talk.L Cheng, RF Hobbs, P Segars, G Sgouros, EC Frey. “Importance of optimization of OS-EM reconstruction for improved dose volume histogram estimates in radionuclide therapy dosimetry”. 12 min oral presentation. SNM 2012, Miami, FL, USA.RF Hobbs, A Tahari, MA Lodge, S Baechler, EC Frey, RL Wahl, G Sgouros. “Uncertainty method and values for whole organ and tumor absorbed doses calculated in 3DRD for 90Y PET/CT dosimetry in selective internal radiation therapy (SIRT).” 12 min oral presentation. SNM 2012, Miami, FL, USA. W van der Weg, R Schoffelen, RF Hobbs, M Gotthardt, DM Goldenberg, RM Sharkey, CH Slump, WJG Oyen, OC Boerman, G Sgouros, EP Visser. “SPECT-based patient-specific red bone marrow (RBM) dosimetry for pre-targeted radioimmunotherapy aiming at predicting and avoiding RBM toxicity”. Oral Presentation NVvTG 2012, Arnhem, Netherlands. W van der Weg, R Schoffelen, RF Hobbs, M Gotthardt, DM Goldenberg, RM Sharkey, WJG Oyen, OC Boerman, G Sgouros, EP Visser. “SPECT-based patient-specific red bone marrow (RBM) dosimetry for pre-targeted radioimmunotherapy aiming at predicting and avoiding RBM toxicity”. Poster Presentation. EANM 2012, Milano, Italy.RF Hobbs, RL Wahl, EC Frey, Y Kasamon, P Huang, RJ Jones, G Sgouros. “Optimized Combination Radiopharmaceutical Therapy Applied to Myeloablative Treatment of Non-Hodgkin’s Lymphoma”. Poster Presentation. EANM 2012, Milano, Italy.RF Hobbs, H Song, G Sgouros. “An Integrated, Pharmacokinetic, Dosimetry and Radiobiological Response Model for Optimization of Targeted Alpha-Particle Therapy of Cancer. 12 min oral presentation, EANM 2012, Milano, Italy. Highlighted talk. RF Hobbs, Y Le, EP Armour, J Efron, N Azad, L Diaz, RL Wahl, G Sgouros, SL Gearhart, JM Herman. “Voxelized dose - FDG-PET response in HDR brachytherapy of rectal cancer”. Poster Presentation. CIRT 2013 Orlando, Florida.RF Hobbs, R Howell,H Song, S Baechler, G Sgouros. “Redefining the relative biological effectiveness (RBE) for alpha-particles in the context of the EQDX formalism”. 15 min oral presentation. TAT 2013, Oak Ridge, Tennessee.RF Hobbs, H Song, G Sgouros. “An Integrated, Pharmacokinetic, Dosimetry and Radiobiological Response Model for Optimization of Targeted Alpha-Particle Therapy of Cancer.” 15 min oral presentation.TAT 2013, Oak Ridge, Tennessee.RF Hobbs, RL Wahl, EC Frey, Y Kasamon, H Song, P Huang, RJ Jones, G Sgouros. “Methodology for Radiobiological Optimization of Combination Radiopharmaceutical Therapy (RPT)”. Poster Presentation. SNM 2013, Vancouver, Canada.G Khorjekar, S Senthamizhchelvan, RF Hobbs, M Orquiza, F Atkins, M Mete, C Garcia, G Sgouros, D Van Nostrand. “Correlation of 124I PET Dosimetry with Clinical Response of 131I Therapy (Tx) for Metastatic Differentiated Thyroid Cancer (DTC)”. 12 min oral presentation. SNM 2013, Vancouver, Canada.S Senthamizhchelvan, RF Hobbs, F Atkins, G Khorjekar, M Orquiza, D Van Nostrand, George Sgouros. “124I-NaI PET/CT based 3-D radiobiological dosimetry (3D-RD) for 131I-NaI therapy of metastatic well-differentiated thyroid cancer”. 12 min oral presentation. SNM 2013, Vancouver, Canada.RF Hobbs. “Small scale modeling as a complement to personalized dosimetry”. 20 min oral presentation. WIPR 2013, Nantes, France.RF Hobbs. “Radiobiologically-based personalized combination therapies”. 20 min oral presentation. WIPR 2013, Nantes, France.RF Hobbs, R Howell, G Sgouros. “A dose-independent relative biological effect quantity for targeted alpha-particle therapy in the EQD2 formalism”. Poster Presentation. AAPM 2013, Indianapolis, Indiana.A Walker, A Chirindel, RF Hobbs, M Huynh-Le, J Moore, M Wharam, SY Cho, S Terezakis. “The use of 18F-FDG PET SUV thresholds for target volume delineation in pediatric Hodgkin lymphoma”. Poster Presentation. ASTRO 2013, Atlanta, Georgia.RF Hobbs, R Howell, H Song, S Baechler, G Sgouros. “Redefining the relative biological effectiveness (RBE) in the context of the EQDX formalism”. 12 min oral presentation. EANM 2013, Lyon, France.RF Hobbs, A Walker, A Chirindel, M Huynh-Le, J Moore, M Wharam, SY Cho, S Terezakis, RL Wahl. “The use of 18F-FDG PET SUV thresholds for target volume delineation in external beam treatment of pediatric Hodgkin’s lymphoma”. 12 min oral presentation. EANM 2013, Lyon, France. J Yue, X Rong, MA Lodge, RF Hobbs, G Sgouros, JFH Geschwind, JM Herman, RL Wahl, EC Frey. “A Comparison of Quantitative Y-90 SPECT and PET Imaging in Post-Therapy Radioembolization of Liver Cancer: Patient Studies.” Oral presentation. IEEE 2013, Seoul, South Korea. ?G Sgouros, RF Hobbs, D Abou. “The Role of Pre-Clinical Models in Radiopharmaceutical Therapy”. Invited oral presentation. ASCO 2014, Chicago, Illinois.DS Abou, H Guerrero-Cazares, J Liu, I Minn, MG Pomper, A Morgenstern, RF Hobbs, G Sgouros. “225Ac imaging of NK1-targeted α-particle for glioblastoma radiotherapy”. 12 min oral presentation. SNMMI 2014, St. Louis, Missouri.A Geyer, RF Hobbs, G Souros, WE Bolch. “Anatomically realistic macroscopic dosimetry models of the kidney for radionuclide therapy”. Poster Presentation. SNMMI 2014, St. Louis, Missouri. RF Hobbs, , Y Le, EP Armour, J Efron, N Azad, L Diaz, RL Wahl, SL Gearhart, JM Herman. “Study of PET response to HDR brachytherapy of rectal cancer.” Poster Presentation. AAPM 2014, Austin, TX.Y Zhang, K Ding, RF Hobbs, X Liang, T Zhu, T McNutt, K Wang. “Commissioning of the Elekta VersaHD linear accelerator.” Poster Presentation. AAPM 2014, Austin, TX.A Geyer, RF Hobbs, G Sgouros, WE Bolch. Radionuclide S values for renal dosimetry based upon NURBS-based anatomical transport models”. Oral presentation. EANM 2014, Gothenburg, SwedenRF Hobbs, DS Abou, A Josefsson, H Song, G Sgouros. “Application of nephron-based dosimetry model for alpha-particle radiopharmaceutical therapy.” Oral presentation. EANM 2014, Gothenburg, SwedenRF Hobbs, G Sgouros, EC Frey, RL Wahl. “Optimized Combination Therapy Applied to 90Y and 177Lu Peptide Receptor Radionuclide Therapy (PRRT) Based on Tumor Size Distribution.” Oral presentation. EANM 2014, Gothenburg, Sweden.J Yue, Y Du, X Rong, RF Hobbs, G Sgouros, RL Wahl, EC Frey. “A Simultaneous Dual-isotope I-131/In-111 Quantitative SPECT Reconstruction Method and Validation with Monte Carlo Simulation”. Oral presentation. IEEE 2014, Seattle, WA.T Mauxion, J Yue, Y Du, RF Hobbs?,?JF Geschwind, JM Herman?,?MA Lodge?,?RL Wahl?, EC Frey. “An Investigation of Tc-99m MAA as a Surrogate for Pre-Therapy Treatment Planning in Y-90 Glass Microsphere Therapy for Liver Cancer.” Oral presentation. IEEE 2014, Seattle, WA.RF Hobbs?,?T Mauxion, R Duran, J Yue, Y Du, JF Geschwind, JM Herman?,?MA Lodge?,?RL Wahl?, EC Frey. “Prospective Absorbed Dose-Based Treatment Planning in Y-90 Microsphere Therapy for Liver Cancer using Tc-99m: A Retrospective Feasibility Study” Oral presentation. 2015, Orlando, FLDS Abou, D Ulmert, RF Hobbs, RC Riddle, DLJ Thorek. “Application and Optimization of Alpha Particle Emitting Radium-223 Dichloride in Models of Prostate Cancer Bone Metasteses”. Submitted to AUA 2015, New Orleans, LA.A Josefsson, RF Hobbs, D Plyku, G Sgouros, M Tatit Sapienza. “Dosimetric analysis using 3D-RD for Ga-68 PRRT and prospective dosimetry for Lu-177 therapy”. Poster Presentation. Ga-68 2015, Baltimore, MD.D Plyku, RF Hobbs, K Huang, F Atkins, C Garcia, G Sgouros, D van Nostrand. “124I-PET/CT based tumor dosimetry for 131I therapy of metastatic differentiated thyroid cancer (DTC) – a comparison of recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal patient preparation methods.” Oral presentation. SNMMI 2015, Baltimore, MD.D Plyku, RF Hobbs, S Senthamizhchelvan, F Atkins, D van Nostrand, G Sgouros. “Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in 124I-PET/CT based 3D radiobiological dosimetry (3D-RD) for 131I therapy of metastatic differentiated thyroid cancer (DTC) – organ dosimetry.” Poster presentation. SNMMI 2015, Baltimore, MD.D Plyku, RF Hobbs, ME Gonzalez, SY Cho, M Pomper, Z Szabo, G Sgouros. “Combined model-based and patient-specific dosimetry for risk evaluation of 18F-DCFPyL-PSMA diagnostic imaging agent for metastatic PCa patients.” Oral presentation. SNMMI 2015, Baltimore, MD.A Josefsson, RF Hobbs, T Mauxion, EC Frey, S Terezakis, C Meyer, DM Loeb, G Sgouros. “Combined treatment planning for 153Sm-EDTMP radiopharmaceutical therapy and external radiation therapy for metastatic osteosarcoma in pediatric patients.” Oral presentation. SNMMI 2015, Baltimore, MD.A Josefsson, RF Hobbs, D Plyku, F Jammes, K Huang, J Amorem de Carvalho, G Barbiero Coura Filho, P Schiavom Duarte, G Sgouros, M Tatit Sapienza, G Sgouros. “Predicting dosimetry for therapy using imaging analogs of therapeutic radiopharmaceuticals: An uncertainty and sensitivity analysis applicable to Theranostics”. Poster presentation. SNMMI 2015, Baltimore, MD.T Mauxion, RF Hobbs?, JM Herman?,?MA Lodge, J Yue, Y Du, RL Wahl?, JF Geschwind, EC Frey. “Comparison of lung shunt fraction (LSF) between pre-therapy Tc-99m MAA and post-therapy SPECT/CT for Y-90 imaging in microsphere (MS) radioembolization”. Oral presentation. SNMMI 2015, Baltimore, MD.T Mauxion, RF Hobbs?,?A Josefsson?,?MA Lodge, RL Wahl, MD Lin, S Kabus, R Duran, JF Geschwind, EC Frey. “Comparison of Tc-99m MAA and Y-90 activity distribution in patients with hepatocellular carcinoma (HCC) treated with transarterial radioembolization (TARE) with glass microspheres (MS)”. Poster presentation. SNMMI 2015, Baltimore, MD.DS Abou, D Ulmert, RF Hobbs, R Riddle, DLJ Thorek. “Microdistribution of Radium-223 Therapy in Models of Prostate Cancer Metastasis”. Oral presentation. SNMMI 2015, Baltimore, MD.A Josefsson, DS Abou, H Song, G Sgouros, RF Hobbs, “Application of nephron-based dosimetry model for Ac-225-7.16.4 alpha-particle radiopharmaceutical therapy of a pre-clinical metastatic breast cancer model.” Poster presentation. 2015, Warsaw Poland.A Josefsson, M Pomper, , G Sgouros, RF Hobbs, “Small scale dosimetry in tumors and kidneys for a pre-clinical model of metastatic prostate cancer using 211At-YC-I-27, a PSMA-targeting ligand.” Oral presentation. TATS 2015, Warsaw Poland.J Yue, EC Frey, T Mauxion, A Josefsson, G Sgouros, RF Hobbs, “Quantitative SPECT Imaging of Ra-223: A Phantom Study.” Oral presentation. TATS 2015, Warsaw Poland.RF Hobbs?,?T Mauxion, R A Josefsson, Duran, J Yue, Y Du, JF Geschwind, JM Herman?,?MA Lodge?,?RL Wahl?, EC Frey. “Prospective Absorbed Dose-Based Treatment Planning in Y-90 Microsphere Therapy for Liver Cancer using Tc-99m: A Retrospective Feasibility Study”. Poster presentation. ASTRO 2015, San Antonio, TX.A Josefsson, G Sgouros, DS Abou, S Park, H Song, DL Huso C Zhu, T B?ck, A Morgenstern, RF Hobbs, “Small scale renal dosimetry for alpha particle radiopharmaceutical therapy of metastatic breast cancer with 225Ac-7.16.4”. Oral presentation. ASTRO 2015, San Antonio, TX.A Josefsson, AP Kiess, Min Il, T B?ck, G Sgouros, M Pomper, RF Hobbs, “Dosimetric analysis for alpha particle radiopharmaceutical therapy for 211At-YC-I-27, a PSMA-targeting ligand for metastatic prostate cancer” Oral presentation. ASTRO 2015, San Antonio, TX.J Yue, EC Frey, T Mauxion, A Josefsson, G Sgouros, RF Hobbs. “Potential for Quantitative Imaging of Ra-223.” Poster presentation. ASTRO 2015, San Antonio, TX.A Parekh, JM Herman, Y Le, M Duhon. RF Hobbs. “Dosimetric comparison of high dose rate (HDR) brachytherapy and intensity-modulated radiation therapy (IMRT) for rectal adenocarcinoma.” Poster presentation. ASTRO 2015, San Antonio, TX.RF Hobbs, A Josefsson, T Mauxion, EC Frey, D Plyka, C Meyer, S Terezakis, G Sgouros, DM Loeb, “Prospective absorbed dose-based combined treatment planning and therapy using?153Sm-EDTMP radiopharmaceutical with external beam radiation therapy in metastatic osteosarcoma patients.” Oral Presentation. RSNA 2105, Chicago, IL.RF Hobbs, A Parekh, Y Le, M Duhon, JM Herman. “Normal organ dosimetric comparison of high dose rate (HDR) brachytherapy and intensity-modulated radiation therapy (IMRT) for rectal adenocarcinoma correlates with relative observed toxicities in HDR.” Oral presentation WBC 2016, San Francisco, CA.RF Hobbs, A Josefsson, T Mauxion, EC Frey, D Plyka, C Meyer, S Terezakis, G Sgouros, DM Loeb, “Preliminary results from a combined?153Sm-EDTMP and external beam radiation therapy for metastatic osteosarcoma patients using prospective absorbed dose-based treatment planning.” Poster presentation WBC 2016, San Francisco, CA.RF Hobbs,A Josefsson, AP Kiess, I Minn, R Mease, M Brummet, G Vaidyanathan, M Zalutsky, M Pomper, “Application of small-scale (sub-organ and cellular level) alpha-particle specific dosimetry model for tumors and kidneys in a pre-clinical model of for 211At-YC-I-27, a PSMA-targeting ligand for metastatic prostate cancer”. Poster presentation WBC 2016, San Francisco, CA.DY Song, Y Le, HJ Bae, RF Hobbs, SK Ng, J Lee, “Dynamic Intraoperative Dosimetry Using Registered Fluoroscopy and Ultrasound: Initial Results of a Phase II Trial”. Oral presentation WBC 2016, San Francisco, CA.AP Kiess, I Minn, G Vaidyanathan, RF Hobbs, A Josefsson, C Shen, M Brummet, Y Chen, J Choi, E Koumarianou, K Baidoo, MW Brechbiel, RC Mease, G Sgouros, MR Zalutsky, MG Pomper, “[211At]YC-I-27 for PSMA-Targeted Alpha-Particle Radiopharmaceutical Therapy”, Oral presentation SNMMI 2016 San Diego, CA.J Yue, RF Hobbs, G Sgouros, EC Frey, “Quantitative SPECT Imaging of Ra-223 in a Phantom.” Poster Presentation. AAPM 2016, Washington, DC.OY Mian, C Gergis, A Ferro, Y Le, S Robertson, RF Hobbs, JL Prince, T McNutt, TL DeWeese, J Lee, DY Song, “A Prospective Study of 80 patients Evaluating Registered Ultrasound and Fluoroscopy (RUF) For Intraoperative Dose Calculation: Improved Accuracy Compared To Conventional Ultrasound-based Intraoperative Dosimetry.” Poster Presentation ASTRO 2016, Boston, MA.A Piotrowski, A Narang, D Jackson, C Gergis, Y Lu, X Ye, RF Hobbs, S Grossman, P Tran, “Small volume (prostate only) radiation for low-intermediate risk and large volume (whole pelvis) radiation for high risk prostate cancer is associated with lymphopenia.” Submitted to SITC/AACR 2016, New York, NY.DY Song, EC Burdette, RF Hobbs, HJ Bae, Y Le, C Haviland, SK Ng, T Heffter, TL DeWeese, J Lee, “A prospective phase 2 trial of dynamic intraoperative dosimetry using registered fluoroscopy and ultrasound: results and comparison with historic control cohort”. Submitted to ESTRO Urology 2016, Milano, Italy.DY Song, HJ Bae, RF Hobbs, Y Le, SK Ng, J Lee, “Phase II Trial of Dynamic Dosimetry for prostate brachytherapy: correlation with post-implant MRI/CT”. Submitted to ESTRO 2017 Vienna, Austria.S Ray, V Kumar, A Lisok, J Chen, I Minn, A Josefsson, M Brummet, B Wharram, S Chatterjee, K Baidoo, M Brechbiel, G Sgouros, RF Hobbs, MG Pomper, “Low- and high-LET radiometal-based therapeutics for metastatic castration-resistant prostate cancer (mCRPC).” Oral Presentation SNMMI 2017 Denver, CO.N Cranston, RF Hobbs, EC Frey, “Development and application of a hepatic vascular tree and particle trapping model with applications to radioembolization treatment planning.” Oral Presentation SNMMI 2017 Denver, CO.JR Nedrow, A Josefsson, S Park, RF Hobbs, F Bruchertseifer, A Morgenstern, G Sgouros, “Reducing renal uptake of free 213Bi associated with the decay of 225Ac-labeled radiopharmaceuticals.” Poster Presentation TATS 2017 Kanazawa, Japan.JR Nedrow, A Josefsson, S Park, T B?ck, RF Hobbs, C Brayton, F Bruchertseifer, A Morgenstern, G Sgouros, “Pharmacokinetic profiling and therapeutic efficacy of alpha-emitter labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model.” Oral Presentation TATS 2017 Kanazawa, Japan.A Josefsson, JR Nedrow, S Park, T B?ck, RF Hobbs, C Brayton, F Bruchertseifer, A Morgenstern,?G Sgouros, “Biodistribution, dosimetry and imaging of?225Ac-DOTA-anti-PD-L1-BC in a murine immunocompetent transgenic breast cancer model.” Poster Presentation TATS 2017 Kanazawa, Japan.A Josefsson, JR Nedrow, RF Hobbs, T B?ck, S Park, F Bruchertseifer, A Morgenstern,?G Sgouros, “Correspondence between alpha-particle emitter dosimetry and normal organ toxicity.” Oral Presentation TATS 2017 Kanazawa, Japan.A Josefsson, JR Nedrow, S Park, F Bruchertseifer, A Morgenstern, G Sgouros, RF Hobbs, “The impact of tumor burden on the absorbed dose to the kidneys to from Actinium-225 labeled antibody therapy.” Poster Presentation TATS 2017 Kanazawa, Japan.A Josefsson, JR Nedrow, S Park, F Bruchertseifer, A Morgenstern, G Sgouros, RF Hobbs, “Actinium-225 labeled antibody therapy micro-scale dosimetry in a murine model and predicted dosimetric impact for human clinical use.” Poster Presentation AAPM 2017 Denver, CO.D Plyku, E Mena, Z Szabo, SP Rowe, MG Pomper, SY Cho, G Sgouros, RF Hobbs, “Combined Model-Based and Patient-Specific Dosimetry for Risk Evaluation of?18F-DCFPyL, a PSMA-Targeted PET Agent for Patients with Metastatic Prostate Cancer (PCa).” Poster Presentation EANM 2017 Vienna, Austria.RF Hobbs, A McGuffie, D Plyku, G Sgouros. “Micro-scale Modeling for the Salivary Gland: Insights into Toxicity from 131I Therapy for Thyroid Cancer.” Oral Presentation EANM 2017 Vienna, Austria.RF Hobbs, A Josefsson, T Mauxion, EC Frey, S Terezakis, C Meyer, DM Loeb, G Sgouros, “Dosimetry and Optimization of Prospective RPT-EBRT?Combination Therapies.” Oral Presentation EANM 2017 Vienna, Austria. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download